Open this publication in new window or tab >>Univ Santiago de Compostela, Ctr Res Biol Chem & Mol Mat CIQUS, Santiago De Compostela 15782, Spain.;Univ Santiago de Compostela, Fac Pharm, Dept Organ Chem, Santiago De Compostela 15782, Spain..
Univ Santiago de Compostela, Ctr Res Biol Chem & Mol Mat CIQUS, Santiago De Compostela 15782, Spain.;Univ Santiago de Compostela, Fac Pharm, Dept Organ Chem, Santiago De Compostela 15782, Spain..
Univ Santiago de Compostela, Ctr Res Mol Med & Chron Dis CiMUS, Santiago De Compostela 15782, Spain.;Univ Santiago de Compostela, Fac Pharm, Dept Pharmacol Pharm & Pharmaceut Technol, Santiago De Compostela 15782, Spain..
Univ Santiago de Compostela, Ctr Res Mol Med & Chron Dis CiMUS, Santiago De Compostela 15782, Spain.;Univ Santiago de Compostela, Fac Pharm, Dept Pharmacol Pharm & Pharmaceut Technol, Santiago De Compostela 15782, Spain..
Univ Barcelona, Inst Neurosci, Fac Med & Hlth Sci, Pharmacol Unit,Dept Pathol & Expt Therapeut, Lhospitalet De Llobregat 08907, Spain.;IDIBELL, Inst Invest Biomed Bellvitge, Neuropharmacol & Pain Grp, Neurosci Program, Lhospitalet De Llobregat 08907, Spain..
Univ Santiago de Compostela, Ctr Res Biol Chem & Mol Mat CIQUS, Santiago De Compostela 15782, Spain.;Univ Santiago de Compostela, Fac Pharm, Dept Organ Chem, Santiago De Compostela 15782, Spain..
Uppsala University, Disciplinary Domain of Science and Technology, Biology, Department of Cell and Molecular Biology, Computational Biology and Bioinformatics.
Univ Santiago de Compostela, Ctr Res Mol Med & Chron Dis CiMUS, Santiago De Compostela 15782, Spain.;Univ Santiago de Compostela, Fac Pharm, Dept Biochem & Mol Biol, Santiago De Compostela 15782, Spain..
Univ Santiago de Compostela, Ctr Res Biol Chem & Mol Mat CIQUS, Santiago De Compostela 15782, Spain.;Univ Santiago de Compostela, Fac Pharm, Dept Organ Chem, Santiago De Compostela 15782, Spain..
Univ Santiago de Compostela, Ctr Res Biol Chem & Mol Mat CIQUS, Santiago De Compostela 15782, Spain.;Univ Santiago de Compostela, Fac Pharm, Dept Organ Chem, Santiago De Compostela 15782, Spain..
Univ Santiago de Compostela, Ctr Res Biol Chem & Mol Mat CIQUS, Santiago De Compostela 15782, Spain.;Univ Santiago de Compostela, Fac Pharm, Dept Organ Chem, Santiago De Compostela 15782, Spain..
Univ Santiago de Compostela, Fac Pharm, Dept Organ Chem, Santiago De Compostela 15782, Spain..
Univ Santiago de Compostela, Ctr Res Mol Med & Chron Dis CiMUS, Santiago De Compostela 15782, Spain..
Univ Barcelona, Inst Neurosci, Fac Med & Hlth Sci, Pharmacol Unit,Dept Pathol & Expt Therapeut, Lhospitalet De Llobregat 08907, Spain.;IDIBELL, Inst Invest Biomed Bellvitge, Neuropharmacol & Pain Grp, Neurosci Program, Lhospitalet De Llobregat 08907, Spain..
Pontificia Univ Catolica Chile, Fac Chem & Pharm, Dept Organ Chem, Santiago 7820436, Chile..
Uppsala University, Disciplinary Domain of Science and Technology, Biology, Department of Cell and Molecular Biology, Computational Biology and Bioinformatics.
Univ Santiago de Compostela, Ctr Res Biol Chem & Mol Mat CIQUS, Santiago De Compostela 15782, Spain.;Univ Santiago de Compostela, Fac Pharm, Dept Organ Chem, Santiago De Compostela 15782, Spain..
Show others...
2023 (English)In: Journal of Medicinal Chemistry, ISSN 0022-2623, E-ISSN 1520-4804, Vol. 66, no 1, p. 890-912Article in journal (Refereed) Published
Abstract [en]
The modulation of the A2B adenosine receptor is a promising strategy in cancer (immuno) therapy, with A2BAR antagonists emerging as immune checkpoint inhibitors. Herein, we report a systematic assessment of the impact of (di- and mono-)halogenation at positions 7 and/or 8 on both A2BAR affinity and pharmacokinetic properties of a collection of A2BAR antagonists and its study with structure-based free energy perturbation simulations. Monohalogenation at position 8 produced potent A2BAR ligands irrespective of the nature of the halogen. In contrast, halogenation at position 7 and dihalogenation produced a halogen-size-dependent decay in affinity. Eight novel A2BAR ligands exhibited remarkable affinity (Ki < 10 nM), exquisite subtype selectivity, and enantioselective recognition, with some eutomers eliciting sub-nanomolar affinity. The pharmacokinetic profile of representative derivatives showed enhanced solubility and microsomal stability. Finally, two compounds showed the capacity of reversing the antiproliferative effect of adenosine in activated primary human peripheral blood mononuclear cells.
Place, publisher, year, edition, pages
American Chemical Society (ACS), 2023
National Category
Medicinal Chemistry Organic Chemistry
Identifiers
urn:nbn:se:uu:diva-520035 (URN)10.1021/acs.jmedchem.2c01768 (DOI)000899518100001 ()36517209 (PubMedID)
Funder
Swedish Cancer Society, CAN 2018/451European Regional Development Fund (ERDF)eSSENCE - An eScience CollaborationThe Cancer Research Funds of Radiumhemmet, 181183Swedish National Infrastructure for Computing (SNIC)
2024-01-112024-01-112026-08-27Bibliographically approved